Abstract:1217 Introduction: Modern cancer immunotherapy using immune checkpoint inhibitors has shown impressive response rates and prolonged survival. However, a considerable number of patients did not respond to the treatment of immune checkpoint inhibitors. Radionuclide labeled immune checkpoint inhibitor assisted treatment strategy will help to maximize its therapeutic effect on solid tumors. A highly tumor-specific αPD-L1 antibody, Y003, was screened by PET imaging and its potential on radioimmunotherapy was also evaluated. Moreover, the adjuvant immunotherapy with 177Lu-DOTA-Y003 were investigated on tumor-bearing mice. Methods: 6-8 weeks old male C57BL/6 mice were subcutaneously injected with 1 × 106cells suspended in 100 µL PBS. When the tumors reached ~500 mm3, mice were intravenously (i.v.) injected with 89Zr-DFO-Y003 (3.7±0.1MBq) and imaged at 2, 12, 24, 48, 72, 96 and 120h. On the fifth day after tumor inoculation, Y003 treatment group mice were intraperitoneally (i.p.) injected with PBS, 5 mg/kg Y003, or 10 mg/kg Y003 every 2 days for 12 days or 6 injections. 177Lu-DOTA-Y003 treatment group mice were developed intravenously (i.v.) with PBS, 3.7MBq 177Lu-DOTA-Y003, or 11.1MBq 177Lu-DOTA-Y003, repeat once a week later. For the Radioimmunotherapy synergized with immunotherapy (Combination therapy) group, mice with 5 days tumor inoculation were injected with 3.7MBq 177Lu-DOTA-Y003 i.v. on the first day and 5mg/kg of Y003 i.p. on the 3rd, 5th, 7th day. A same treatment course was repeated on 13th day. When the tumor volume reaches 1000mm3, the mouse is regarded as death, and the survival curve is drawn. The activity level and body weights of the micewere monitored for toxicity. Tumors and spleens were harvested on 2 days after injection of 177Lu-DOTA-Y003for the flow cytometry assay for immune response. Results: Y003 alone and 177Lu-DOTA-Y003 alone have modest therapeutic effect, while 177Lu-DOTA-Y003 adjuvant radioimmunotherapy group showed remarkable results: tumor growth significantly slowed down, the survival of 177Lu-DOTA-Y003 adjuvant radioimmunotherapy group was prolonged significantly, and the survival rate was 100% at 36 days post-treatment, while all of the other groups died, indicating that the treatment effect of 177Lu-DOTA-Y003 adjuvant radioimmunotherapy was significant. The average survival time of 177Lu-DOTA-Y003 adjuvant radioimmunotherapy group was also significantly prolonged. Conclusions: 177Lu-DOTA-Y003 adjuvant immunotherapy could achieve double effects, especially at low radiation and antibody doses.

Anti-Tumor Effect Of Integrin Targeted Lu-177-3prgd(2) And Combined Therapy With Endostar

Anti-tumor Effect of Integrin Targeted 177Lu-3Prgd2 Radionuclide Therapy by a Combined Treatment with Angiogenesis Inhibitor, Endostar, in Human Glioblastoma Xenograft

Modulating Tumour Vascular Normalisation Using Triptolide-Loaded NGR-functionalized Liposomes for Enhanced Cancer Radiotherapy

An Experimental Research into Endostatin Microbubble Combined with Focused Ultrasound for Anti-Tumor Angiogenesis in Colon Cancer

Enhancement of therapeutic efficacy by combination of integrin α vβ 3-targeted radiotherapy and anti-PD-L1 immunotherapy: a preclinical study

Two ⁹⁰Y-Labeled Multimeric RGD Peptides RGD4 and 3PRGD2 for Integrin Targeted Radionuclide Therapy.

Nuclear Imaging of PD-L1 Expression Promotes the Synergistic Antitumor Efficacy of Targeted Radionuclide Therapy and Immune Checkpoint Blockade

Integrin α v β 3 -targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy.

PET Imaging of Neovascularization with 68Ga-3Prgd2 for Assessing Tumor Early Response to Endostar Antiangiogenic Therapy

Evaluating the Effects of an Angiogenesis Inhibitor of Endostar with a Novel RGD Dimer Probe Labeled by 99Tcm

Scintigraphic Imaging of Neovascularization With 99mTc-3PRGD2 for Evaluating Early Response to Endostar Involved Therapies on Pancreatic Cancer Xenografts In Vivo

Combination of [177Lu]Lu-DOTA-TATE Targeted Radionuclide Therapy and Photothermal Therapy as a Promising Approach for Cancer Treatment: In Vivo Studies in a Human Xenograft Mouse Model

177Lu-Labeled PD-L1 Antibody Synergizes with an Immune Checkpoint Inhibitor for Colorectal Tumors

Synergistic Retention Strategy of RGD Active Targeting and Radiofrequency-Enhanced Permeability for Intensified RF & Chemotherapy Synergistic Tumor Treatment.

Potential Therapeutic Radiotracers: Preparation, Biodistribution and Metabolic Characteristics of 177 Lu-labeled Cyclic RGDfK Dimer

SPECT Imaging of Neovascularization With 99mTc-3PRGD2 for Evaluating Early Response to Endostar Involved Therapies on Pancreatic Cancer Xenografts in Vivo

Optimum Combination of Radiopharmaceuticals‐Based Targeting‐Triggering‐Therapy Effect and PD‐L1 Blockade Immunotherapy

Tc-3PRGD SPECT Predicts the Outcome of Endostar and Cisplatin Therapy in Xenograft Animals

99Mtc-3Prgd2 SPECT Predicts the Outcome of Endostar and Cisplatin Therapy in Xenograft Animals

Synergism of 64Cu-Labeled RGD with Anti-PD-L1 Immunotherapy for the Long-Acting Antitumor Effect

Safety, Dosimetry, and Efficacy of an Optimized Long-Acting Somatostatin Analog for Peptide Receptor Radionuclide Therapy in Metastatic Neuroendocrine Tumors: from Preclinical Testing to First-in-human Study